Genomic and Clinicopathologic Characterization of ATM-deficient Prostate Cancer.

Harsimar KaurDaniela C SallesSanjana MuraliJessica L HicksMinh NguyenColin C PritchardAngelo M DeMarzoJerry S LanchburyBruce J TrockWilliam B IsaacsKirsten M TimmsEmmanuel S AntonarakisTamara L Lotan

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

ATM loss is enriched among high-grade prostate cancers. Optimal evaluation of ATM status requires both genomic and IHC studies and will guide development of molecularly targeted therapies.

Keyphrases

prostate cancer
dna damage
high grade
dna damage response
dna repair
radical prostatectomy
copy number
low grade
oxidative stress
young adults
benign prostatic hyperplasia